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Background. Weekly rifapentine plus isoniazid for 3 months (3HP) is as effective as daily isoniazid for 9 months
(9H) for latent tuberculosis infection in high-risk persons, but there have been reports of possible flu-like syndrome.
Methods. We identified clinically significant systemic drug reactions (SDR) and evaluated risk factors in patients
who did not complete treatment in the PREVENT Tuberculosis study.
Results. Among 7552 persons who received≥1 dose of study drug, 153 had a SDR: 138/3893 (3.5%) with 3HP vs 15/
3659 (0.4%) with 9H (P < .001). In the 3HP arm, 87 (63%) had flu-like syndrome and 23 (17%) had cutaneous reactions;
13/3893 (0.3%) had severe reactions (6 were hypotensive) and 6 reported syncope. Symptoms occurred after a median of
3 doses, and 4 hours after the dose; median time to resolution was 24 hours. There were no deaths. In multivariate logistic
regression analysis, factors independently associated with SDR included receipt of 3HP (adjusted odds ratio [aOR] 9.4;
95% confidence interval [CI], 5.5, 16.2), white non-Hispanic race/ethnicity (aOR 3.3; 95% CI, 2.3, 4.7), female sex (aOR
2.0; 95% CI, 1.4, 2.9), age ≥35 years (aOR 2.0; 95% CI, 1.4, 2.9), and lower body mass index (body mass index [BMI];
P = .009). In a separate multivariate analysis among persons who received 3HP, severe SDR were associated with white
non-Hispanic race/ethnicity (aOR 5.4; 95% CI, 1.8, 16.3), and receipt of concomitant non-study medications (aOR
5.9; 95% CI, 1.3, 27.1).
Conclusions. SDR were more common with 3HP, and mostly flu-like. Persons of white race, female sex, older age,
and lower BMI were at increased risk. Severe reactions were rare and associated with 3HP, concomitant medication, and
white race. The underlying mechanism is unclear.
Clinical Trials Registration. NCT00023452.
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Once-weekly rifapentine plus isoniazid for 3 months
(3HP) is effective against latent Mycobacterium tuber-
culosis infection [1–3] and is an alternative to 9 months
of daily isoniazid (9H) [4].The PREVENT Tuberculosis
study was a randomized open-label trial of once-weekly
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directly-observed 3HP vs daily self-administered 9H [1]. Early
in the trial there were reports of possible drug hypersensitivity
or flu-like syndrome. This had not been reported with rifapen-
tine plus isoniazid for the treatment of active tuberculosis [5, 6].
A “flu-like syndrome” characterized by fever, chills, fatigue,
malaise, headache, myalgia, and arthralgia has been reported
with intermittent, high doses of rifampin [7–14]. Among
persons receiving once-weekly rifampin as part of their anti-
tuberculosis regimen, a flu-like syndrome developed among
35%–57% of persons who received 1200–1800 mg of rifampin,
22%–31% of those who received 900 mg, and 10% of those who
received 600 mg rifampin once-weekly [11]. In contrast, among
persons treated with twice-weekly rifampin plus isoniazid, flu
syndrome was reported in 8% of those receiving 900 mg and
4% of those receiving 600 mg rifampin [11].
The rifampin flu-like syndrome usually develops after 3–6
monthsof treatment [11,15].Itmaybe less commoninpatientswho
initially have lower, daily dosing [5, 12, 16, 17]. Patients who devel-
op the syndrome on high-dose intermittent regimens often subse-
quently tolerate lower daily dosing [15]. This is different from the
severe immunologically-mediated reaction to other drugs, which
typically occurs within 2 months, is less dependent on dose,
and often intensifies with continued and subsequent exposure
following a reaction [18, 19]. Symptoms with rifampin appear
1–2 hours after drug administration and last up to 8 hours [9,
11]. These symptoms are more common in women than men,
and the incidence increases with age [20–22].
There have also been case reports of a flu syndrome with iso-
niazid [23–29]. Manifestations include pruritic rash, appetite
loss, myalgia, arthralgia, fatigue, weight loss, malaise, headache,
fever, red eyes, leukocytosis, and hypotension.
We sought to evaluate reactions with systemic manifesta-
tions in all participants in the PREVENT Tuberculosis clinical




The PREVENT Tuberculosis study was a prospective, open-
label, randomized trial of 3 months of once-weekly rifapentine
900 mg (graduated dosing for persons ≤50 kg) plus isoniazid
15–25 mg/kg (rounded up to nearest 50 mg; 900 mg maximum)
given under direct observation (3HP), compared to 9 months of
daily self-administered isoniazid 5–15 mg/kg (rounded up to
nearest 50 mg; 300 mg maximum) (9H). Persons ≥12 years of
age with latent M. tuberculosis infection were enrolled between
June 2001 and February 2008. Participants from one PREVENT
Tuberculosis study site were excluded from this analysis due to
discrepancies regarding receipt of study drug and directly-
observed therapy. The PREVENT Tuberculosis study and a
dedicated substudy were approved by the institutional review
boards of the Centers for Disease Control and Prevention
(CDC) and all study sites. Written informed consent was ob-
tained from all study participants.
Information about adverse events (AE) was collected monthly
during treatment and until 30 days after last study dose, graded
by the Cancer Therapy Evaluation Program common toxicity cri-
teria [30]. All AE from patients who received ≥1 dose of study
drug were included in this analysis. Details have been published
previously [1]. All AE, excluding pregnancies and dosing errors,
were evaluated. The events were classified as attributed to study
drugs (definitely, probably, or possibly) or not-attributed to study
drugs (unlikely, non-related, or unclassifiable), as reported by the
local site investigator (Supplementary Table 1). To focus on clin-
ically significant systemic reactions, isolated hepatotoxicity, iso-
lated rash, AE with known non-drug cause, AE of grade 1
severity [30], and events in participants able to complete treat-
ment (11 doses in the 3HP arm or 240 doses in the 9H arm),
were excluded. The Naranjo adverse drug reaction probability
scale [31] was used to objectively evaluate AE regardless of regi-
men. The scale was modified to increase specificity for possible
hypersensitivity events (Supplementary Table 2). AE with low
score (≤5) were excluded. In addition, after the first AE reports
of possible hypersensitivity had been received and no clear defi-
nition was available, the PREVENT Tuberculosis sub-study pro-
tocol team established two broad criteria for such a drug reaction;
(1) hypotension (systolic blood pressure <90 mm Hg), urticaria
(hives), angioedema, acute bronchospasm, or conjunctivitis
(red eyes); and (2) >4 of the following symptoms occurring con-
currently (>1 of which had to be grade 2 or higher): weakness,
fatigue, nausea, vomiting, headache, fever, aches, sweats, dizzi-
ness, shortness of breath, flushing, or chills. AE that met either
of the above criteria were termed systemic drug reactions (SDR).
Severe AE were defined as those resulting in hospitalization,
hypotension (systolic blood pressure <90 mm Hg) or loss of
consciousness, anaphylaxis, or grade 4 toxicity [30].Anaphylax-
is was defined as at least one major dermatological reaction and
at least 1 cardiovascular and/or respiratory criterion [32].
SDR were classified in one of five hierarchical and mutually
exclusive categories: cutaneous, flu-like, gastrointestinal, respi-
ratory, or not defined (see Table 2 for definitions) [13, 15]. Con-
comitant medications received before or up to 7 days after the
SDR (the latter to ensure capture of medications received prior
to the event) were recorded and coded according to the WHO
Drug B2 Herbal / DDE drug dictionary (June 2010 version).
Vitamins, calcium carbonate, mineral supplements, and antiox-
idants were considered nonstudy concomitant medications and
included in the analysis. Medications given to treat AE were not
considered concomitant medications. An in-depth study record
review was performed (by R. M., E. P., G. S., N. F. A., M. E. V.)
for all AE attributed to study drugs. Drug rechallenge was
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allowed at the discretion of the site study investigators (See
guidelines for re-challenge in the Supplemental Material, in-
cluding Figure 1). Drug restart was defined as receipt of the
full protocol-recommended regimen after the event.
Statistical Analysis
Categorical variables were compared using the Pearson’s chi-
squared test. Continuous variables were compared using the
2-sample Kolmogorov—Smirnov (asymptotic) nonparametric
Figure 1. Adverse events (AE) evaluated in the PREVENT Tuberculosis study. aCompletion of treatment definition: 11/12 doses in the 3HP or 240/270 in
the 9H arm; bCriteria for possible hypersensitivity: (1) hypotension (systolic blood pressure <90 mm Hg), urticaria, angioedema (defined as swelling around
the lips or eyes), acute bronchospasm, or conjunctivitis (red eyes); or (2) ≥4 of these symptoms concurrently, ≥1 of which was grade 2 or higher: weakness,
fatigue, nausea, vomiting, headache, fever, aches, sweats, dizziness, shortness of breath, flushing, or chills; cSevere Adverse Event: hospitalization, hypo-
tension (systolic blood pressure <90 mmHg) or loss of consciousness, anaphylaxis, or grade 4 toxicity. These categories were not mutually exclusive; d3HP:
3 months of once-weekly rifapentine plus isoniazid given under direct observation; e9H: 9 months of daily isoniazid given self-administered; fOne report was
received after the 6 cases of hypotension reported in the parent PREVENT Tuberculosis study. Abbreviation: ADR, adverse drug reaction.
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test [33]. Univariate and multivariate logistic regression analyses
were performed; clinically important variables (HIV infection
and smoking) and all variables with P < .05 in the univariate
analysis were included in the multivariate model. Interaction
terms between study arms and all factors were also included in
the multivariate model; this analytical strategy reveals whether
arm-specific associations are statistically different between
arms; this comparison is not possible in stratified analysis [34].
To control for variations among enrolling sites, we constructed
a generalized linear mixed model where each site was treated as
a random effect [35]. In addition, an analysis of residuals was
used to analyze age as a continuous variable; no pattern was iden-
tified, so median age of the study population was used in the
model. Body mass index (BMI) was evaluated as a continuous
variable but grouped according to standard categories [36]. A
cluster analysis clustered participants with similar signs and
symptoms (Supplemental Material) [37]. A nonparametric test
compared the time of SDR onset after the last dose ingested,
and the time to resolution. Statistical analyses were conducted
using SAS version 9.3; the cluster analysis was performed using R.
RESULTS
Among the 7552 (3HP = 3893 and 9H = 3659) study partici-
pants who received ≥1 dose of study drug, there were 1520
AE reported. After excluding pregnancies (n = 117) and dosing
errors (n = 68), 809 were reported as nonattributed and 526 at-
tributed to study drugs. No SDR were identified in the nonat-
tributed group, although 6 events could not be evaluated due to
limited data. Of 526 AE attributed to study drugs, 153 SDR oc-
curred in 153 individual participants (2.0% of all 7552 partici-
pants): 138/3893 (3.5%) in the 3HP arm vs 15/3659 (0.4%) in
the 9H (P < .001) (Figure 1 and Table 1). There were 14 severe
SDR, of which 13 occurred in the 3HP arm (13/3893 = 0.3%).
Among the 138 events in the 3HP arm, 23 (17%) were cuta-
neous and 87 (63%) were flu-like syndrome. In contrast, among
the 15 events in the 9H arm, 9 (60%) were cutaneous and 2
(13%) were flu-like (Table 2). Of the 138 participants in the
Table 1. Adverse Events Attributed to Study Drug Among PREVENT
Tuberculosis Participants—by Study Arm
3HP 9H
Received ≥1 dose study drug 3893 3659
AE attributable to study drug 327 (8.4%) 199 (5.4%)
Hepatotoxicity 17 97
Rash only 31 21
Toxicity grade 1 39 27
Other known reason for AE 31 5
Completed treatment 27 3
Naranjo score <5, Possible or
Doubtfula
21 8
Did not meet possible HS criteria
1) or 2)
20 22
Repeated events 3 1
Systemic drug reactions 138 (3.5%) 15 (0.4%)
Met possible HS criterion 1b 63 (1.6%) 9 (0.2%)
Met only HS criterion 2c 75 (1.9%) 6 (0.2%)
Clinically severe events (n = 14)d 13 1
Hospitalization 4e 1
Hypotension or loss of consciousness 7 0
Anaphylaxis 0 0
Grade 4 toxicity 8f 0
There were 6 cases of hypotension and 6 reported syncopal events (2 syncopal
episodes were severe events); these 12 episodes did not overlap. One case of
syncope had loss of consciousness.
Abbreviations: AE, adverse event; HS, hypersensitivity.
a Of those who remained, AE among participants receiving 3HP: Highly
probable (22), Probable (134); AE among participants receiving 9H: Highly
probable (0), Probable (35).
b Includes 1 case of syncope.
c Includes 5 cases of syncope.
d The categories are not mutually exclusive.
e Includes 0 cases of syncope.
f Includes 1 case of syncope.
Table 2. Characterization of the 153 Systemic Drug Reactions
According to Syndrome
3HP (n = 138) 9H (n = 15)
Cutaneousa 23 (17%) 9 (60%)
Severe 3 1
Nonsevere 20 8
Flu-likeb 87 (63%) 2 (13%)
Severe 6 0
Nonsevere 81 2
Gastrointestinalc 7 (5%) 1 (7%)
Severe 2 0
Nonsevere 5 1
Respiratoryd 5 (4%) 0 (0%)
Severe 1 0
Nonsevere 4 0
Not definede 16 (12%) 3 (20%)
Severe 1 0
Nonsevere 15 3
The syndromes were compiled from definitions in the literature and the study
protocol.
The syndromes were hierarchically ordered (as presented below) and mutually
exclusive.
a Angioedema, urticaria, rash and itching, or anaphylaxis (defined as cutaneous
plus circulatory or respiratory reaction) that occurred within 24 hours of the
study dose.
b Presence of (fever or chills) and (weakness, fatigue or muscle pain) and
(aches, syncope, heart rate >100, palpitations, flushing, dizziness, conjunctivitis
(red eyes), or sweats). This includes 6 syncope events.
c Presence of vomiting (with or without nausea) or abdominal pain.
d Bronchospasm, cough, shortness of breath, or chest pain.
e Did not meet any of the above definitions.
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3HP arm who developed an SDR, 73 were re-challenged with
study drug (Supplementary Table 3). Of the 51 participants ini-
tially rechallenged with rifapentine, 36 (71%) tolerated it. Of the
20 participants initially rechallenged with isoniazid, 3 (15%) tol-
erated it. Only 2/73 (3%) tolerated both isoniazid and rifapentine
on re-challenge, and none completed study treatment. In addi-
tion, none of the 153 study participants who developed an
SDR completed study treatment, per study criteria. Data on
whether an alternative regimen was completed were not available.
Persons developing an SDR were more likely to receive 3HP,
were older, more likely to be female, of white non-Hispanic
race/ethnicity, and to receive concomitant nonstudy medication
(Supplementary Table 4). Among persons developing an SDR,
the event occurred after a median of 3 once-weekly doses in the
3HP arm and 16 daily doses in the 9H arm (Table 3). In the
3HP arm, the median time from drug ingestion to symptom
onset was 4 hours, and the median time from symptom onset
to resolution was 24 hours (Table 3). There was no difference
in time to symptom resolution among those who did vs did
not develop fever (data not shown).
Signs and symptoms of the SDR are in Supplementary
Table 5. In the 3HP arm, fatigue, headache, nausea, weakness,
chills, and myalgia were most common. All of the signs and
symptoms were associated in the cluster analysis, distinct
from a cluster that included rash and itching. Fever (>100°F)
was present in approximately half.
There were 3 persons younger than 18 (age range 14–17): 2
received 3HP and 1 received 9H; none developed a severe event
and all recovered in <24 hours.
The univariate and multivariate logistic regression analysis of
risk factors for SDR are in Tables 4 and 5. In the multivariate
Table 3. Time to Symptom Onset and Resolution of Systemic Drug Reactions
Event 3HP (N = 138) 9H (N = 15) P Valuea
Median doses received prior to event onset (IQR) 3 (2.0–5.0) (n = 138) 17 (9–57.0) (n = 15) NAb
Median time from drug ingestion to event onset (hours; IQR) 4 (1.0–8.0) (n = 135) 1.5 (1.0–13.5) (n = 8) .60
Median time to symptom resolution (hours; IQR) 24 (12–48) (n = 132) 24 (2–48) (n = 11) .89
Median time to symptom resolution—nonsevere events (n = 139) (hours; IQR) 24 (12–62) (n = 119) 36 (12–48) (n = 10) . . .
Median time to symptom resolution—severe events (n = 14) (hours; IQR) 21 (6–24) (n = 13) 2 (n = 1) . . .
Abbreviation: IQR, interquartile range.
a Two sample Kolmogorov–Smirnov (Asymptotic) test, a nonparametric test due to the small sample size and not normally distributed.
b NA: Not applicable since the comparison is between regimens with different dosing intervals.
Table 4. Univariate Logistic Regression Analysis of Risk Factors
for Systemic Drug Reactions
OR 95% CI P Value
3HP (n = 3893) vs 9H (n = 3659) 8.9 5.2, 15.2 <.001
White-non-Hispanic race 3.4 2.4, 4.8 <.001
Female sex 2.1 1.5, 2.9 <.001
Age ≥35 y (mediana) 2.0 1.4, 2.8 <.001
Body mass index .03
18.5–24.9 (normal) reference
<18.5 (underweight) 0.8 .3, 1.8 .55
25–29.9 (overweight) 0.5 .4, .8 .004
≥30 (obese) 0.9 .6, 1.3 .58
Any concomitant nonstudy drug 1.6 1.1, 2.2 .006
HIV infection 0.3 .04, 2.3 .25
Smoking 1.0 .7, 1.5 .99
There were 153 systemic drug reactions among 7552 study participants.
There was no interaction between age and receipt of concomitant nonstudy
drugs.
Abbreviations: CI, confidence interval; HIV, human immunodeficiency virus;
OR, odds ratio.
a Of the 7552 study participants.
Table 5. Multivariate Logistic Regression of Risk Factors for
Systemic Drug Reactions
Adjusted OR 95% CI P Value
3HP vs 9H 9.4 5.5, 16.2 <.001
White-non-Hispanic race 3.3 2.3, 4.7 <.001
Female sex 2.0 1.4, 2.9 <.001
Age ≥35 y (mediana) 2.0 1.4, 2.9 <.001
Body mass index (BMI) .009
18.5–24.9 (normal) reference
<18.5 (underweight) 0.9 .4, 2.2 .88
25–29.9 (overweight) 0.5 .3, .7 .001
≥30 (obese) 0.7 .4, 1.0 .05
Any concomitant non-study drug 1.2 .8, 1.7 .33
There were 153 systemic drug reactions among 7552 persons.
The model also included HIV infection and smoking because of their potential
role in systemic drug reactions, but these variables were not statistically
significant. We tested for the following possible individual interactions:
a) regimen with race, sex, age, concomitant medications, BMI, HIV, smoking;
b) concomitant medications with race, sex, and age. The only interaction was
between regimen and sex, therefore the results (Table 6) are presented for
each category of regimen and sex.
Abbreviations: CI, confidence interval; HIV, human immunodeficiency virus;
OR, odds ratio.
a Of the 7552 study participants.
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analysis, factors independently associated with these reactions
were receipt of 3HP, white race, female sex, age ≥35 years,
and lower BMI. To control for variations according to study
site, a generalized linear mixed model was performed; results
were similar (data not shown). In the multivariate analysis, an
interaction between regimen and sex was noted; the risk of SDR
according to regimen and sex is in Table 6. After adjusting for
the variables in the multivariate model, among those receiving
9H, the risk of SDR was 15-fold higher in women than men.
Among those receiving 3HP, the risk of SDR was approximately
twice as high in women as men. In those persons at highest risk
of SDR (white non-Hispanic women >35 years old who received
3HP), the probability of developing SDR was 12.3% (95% CI,
8.1%, 24.4%) (Supplementary Table 6).
Severe SDR were uncommon. Among the 13 persons who re-
ceived 3HP and developed a severe SDR, the median number of
doses received before event onset was 5. Six persons developed hy-
potension, and 2 others reported syncope. The lowest reported
systolic blood pressure was 70 mmHg (in one participant), though
none required vasopressor support and the median time to recov-
ery was 24 hours. Overall, 6 persons were reported to develop syn-
cope, of whom 2 had severe SDR; none of them had documented
hypotension and all of them recovered in <24 hours. Only one of
the 6 episodes of syncope had loss of consciousness.
There were no deaths or permanent sequelae from SDR;
there were no instances of Stevens-Johnson syndrome, toxic
epidermal necrolysis, or drug reaction with eosinophilia and
systemic symptoms, and no episodes of acute renal failure,
bleeding due to thrombocytopenia, or hemolytic anemia.
There was 1 episode each of thrombocytopenia (without evi-
dence of bleeding), anemia (not hemolytic), and neutropenia
(see Supplemental Material for details). There were no reports
of renal failure.
In a logistic regression analysis of predictors of clinically se-
vere SDR among persons who received 3HP, white non-Hispanic
race/ethnicity and concomitant nonstudy medication were the
only statistically significant variables (Table 7). Of the 14 per-
sons who developed clinically severe SDR, 9 (64%) received
≥2 concomitant medications. Of the 28 concomitant medica-
tions received, 14 (50%) were for the alimentary tract/metabo-
lism and 8 (29%) were for cardiovascular indications. There was
Table 6. Final Multivariate Logistic Regression Model of Risk
Factors for Systemic Drug Reactions, Evaluating Regimen by Sex
Adjusted OR 95% CI P Value
Regimen – sex <.001
9H male (reference) . . .
9H female 15.1 2.0, 115.5 .009
3HP male 53.4 7.4, 386.3 <.001
3HP female 94.4 13.1, 680.6 <.001
White-non-Hispanic 3.3 2.3, 4.7 <.001
Age ≥35 y (mediana) 2.0 1.4, 2.9 <.001
Body mass index .01
18.5–24.9 (normal) reference
<18.5 (underweight) 0.9 .4, 2.3 .9
25–29.9 (overweight) 0.5 .3, .7 .001
≥30 (obese) 0.7 .5, 1.0 .05
There were 153 systemic drug reactions among 7552 persons.
This model included HIV infection, use of any concomitant medication, and
smoking, but these variables were not statistically significant.
Abbreviations: CI, confidence interval; HIV, human immunodeficiency virus;
OR, odds ratio.
a Of the 7552 study participants.
Table 7. Univariate and Multivariate Logistic Regression Analysis of Predictors of Clinically Severe Systemic Drug Reactions (n = 13)
Among 3893 Study Participants Who Received ≥1 Dose of the 3HP Regimen
Univariate Multivariate
OR 95% CI P Value Adjusted OR 95% CI P Value
White non-Hispanic 7.4 2.5, 22.0 <.001 5. 1.8, 16.3 .003
Female sex 1.4 .5, 4.3 .51 . . . . . . . . .
Age ≥35 y (mediana) 2.1 .6, 6.7 .23 . . . . . . . . .
Any nonstudy concomitant medicationb 7.8 1.7, 35.4 .008 5.9 1.3, 27.1 .02
BMI (per 1 unit increase) 1.0 .9, 1.1 .69
Smoking 0.2 .03, 1.7 .15 . . . . . . . . .
Of those concomitant medications reported by persons who developed a severe event, 52% were classified as for the alimentary tract/metabolism (including
vitamins) and 28% were classified as cardiovascular.
Prior to performing these analyses among persons who received 3HP, the following interactions were evaluated among the full dataset of 7552 participants, but
none were statistically significant: (1) regimen with race, sex, age, concomitant medication, BMI; (2) concomitant medication with race, sex, age; (3) BMI with sex.
Abbreviations: BMI, body mass index; CI, confidence interval; OR, odds ratio.
a Of the 7552 study participants.
b This includes concomitant medications given before or up to 7 days after the onset date. Medications to treat adverse events were excluded.
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no predominant medication or medication class associated with
severe SDR. In those persons at highest risk of severe SDR
(white non-Hispanic persons who received 3HP plus concom-
itant medications), the probability of developing SDR was 1.8%
(95% CI, .9%, 4%) (Supplementary Table 6).
DISCUSSION
In the PREVENT Tuberculosis study SDR were uncommon but
occurred significantly more frequently among persons who re-
ceived 3HP than 9H. Among persons in the 3HP arm, the
most common presentation was flu-like syndrome, which ac-
counted for 63% of the SDR episodes. These reactions were asso-
ciated with female sex, white non-Hispanic race/ethnicity, age
≥35 years old, and lower BMI. Female sex, white race, and
increased age have been reported as risk factors for flu-like
syndrome among persons who received intermittent rifampin—
usually at high doses and given together with isoniazid or etham-
butol [11, 12, 15, 20, 38]. In 2 recent studies of 3HP for treatment
of latentM. tuberculosis infection, there were no reports of flu-like
syndrome, but both studies were smaller than PREVENT Tuber-
culosis and were conducted in Brazil and South Africa; very few
white women of older age were enrolled [2, 3]. The inconsistency
in reproducibility of symptoms upon single and multiple drug
rechallenge, female sex, the association with lower BMI, and
the successful completion of treatment in many patients without
morbidity despite the previous adverse drug reactions, suggest
that the SDR and flu-like symptoms may not be immunologically
mediated. This SDR differs from flu-like syndrome associated
with immunologically mediated reactions such as with abacavir,
where there is significant intensification with continued dosing
and severe re-challenge morbidity [19]. However, the possibility
of an immune-mediated reaction cannot be ruled out.
Previous reports of the rifampin flu-like syndrome noted a pos-
sible association with rifampin antibodies [39, 40]. However, the
presence of antibodies in persons who have received and tolerated
antibiotics is relatively common, and of uncertain importance.
Isoniazid can rarely cause a classic delayed immunologically
mediated drug hypersensitivity reaction. Although it can be as-
sociated with fever and flu-like symptoms, it can have features
distinct from the SDR described in this study, such as skin erup-
tions, lymphadenopathy, hepatitis, and eosinophilia [23, 24, 27–
29, 41]. Isoniazid can also interact with foods rich in mono-
amines, particularly tyramine [25, 42, 43].
Given the similarity of published reports of flu-like syndrome
associated with rifampin and the reactions seen in this study, and
given the 9-fold greater frequency of such reactions in the 3HP
arm, one might expect rifapentine to more likely cause these
symptoms than isoniazid. However, rifapentine was better toler-
ated than isoniazid on rechallenge (Supplementary Table 3). In
a recent multicenter randomized clinical trial of intermittent
continuation-phase therapy after 2 months of daily therapy, par-
ticipants (64% of whom were black males) received 900 mg rifa-
pentine twice-weekly or 1200 mg rifapentine once-weekly, both
in combination with moxifloxacin, pyrazinamide, and ethambu-
tol (not isoniazid). There were no reports of possible hypersensi-
tivity or flu-like syndrome [44] (Amina Jindani, unpublished
data), but it is possible that the lack of flu-like syndrome was
due to the regimens or the population studied.
There were 14 patients with clinically severe reactions: 13/3893
(0.3%) in the 3HP arm and 1/3659 (0.03%) in the 9H arm.
Among the 13 episodes in the 3HP arm, 4 patients were hospi-
talized and 6 developed hypotension. However, most recovered
within 24 hours without sequelae. Basic data (onset date, serious-
ness, attribution) on all AE in the PREVENT Tuberculosis study
were collected systematically and prospectively; however, addi-
tional data (eg, symptoms on rechallenge, vital signs) were retro-
spectively and not uniformly collected for severe SDR. This could
have contributed the lack of reports of hypotension among those
with reported syncope. Decisions regarding rechallenge in partic-
ipants with SDR were made by the site investigator. About half of
participants with an SDR, including the severe events, were not
rechallenged. Therefore, it is difficult to ascertain whether isoni-
azid, rifapentine, or their combination was the cause of SDR. We
were also unable to determine whether there were early clinical
predictors of subsequent SDR, including severe reactions, since
symptoms of adverse drug reactions were ascertained monthly,
and the median time to onset in the 3HP arm was before the
first monthly visit (week 3). Whether particular symptoms pre-
dict subsequent SDR, and discontinuation of treatment in per-
sons with such symptoms decreases SDR risk merits further
investigation. It would also appear that SDR would not be miti-
gated by directly observed therapy, because the median time to
symptom onset was 4 hours, and the healthcare worker would
likely not be present at that time.
Clinically severe SDR were associated with receipt of 3HP,
concomitant nonstudy medications, and white non-Hispanic
race/ethnicity. These associations merit further investigation.
Although half of the patients received concomitant medica-
tions, we found no association with receipt of a particular med-
ication or medication class.
There were several limitations of this study. First, it was a post
hoc analysis of data collected in an open-label clinical trial. It is
difficult to know if the open label design led to under- or over-
estimation of endpoints. Additional data on severe SDR were
not systematically collected on all study participants specifically
related to possible flu-like syndrome. Second, there was no case
definition for this syndrome at the start of the study. However, a
case definition was developed during the trial, after the first re-
ports of flu-like syndrome were identified. Third, drug levels
that correlate with drug exposure were not obtained in this
study. Fourth, the data instruments for surveillance of AE in
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the clinical trial were not well-suited to investigate potentially
novel clinical syndromes.
In conclusion, SDR in the PREVENT Tuberculosis study oc-
curred primarily among persons who received 3HP, were mostly
flu-like, did not meet objective drug hypersensitivity criteria,
and had features that differ from severe immunologically medi-
ated drug reactions. Most SDR were mild and resolved within 24
hours. Attribution to rifapentine or isoniazid separately or to-
gether is not possible with the available data, though the syn-
dromes observed were similar to those reported previously
with rifampin. Persons of white race, female sex, increased
age, and lower BMI were at increased risk. Severe reactions
were rare and appeared to be associated with the receipt of con-
comitant medication and white race. As 3HP is introduced into
clinical practice, including populations that differ from our
study population, clinical monitoring and continued vigilance
for SDR are warranted.
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